Trading of Aptorum Group was halted at 10:39 AM EST due to "LULD pause". Aptorum Group (APM) Competitors $3.39 +2.42 (+249.87%) As of 02:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock APM vs. PHGE, FNCH, VYNE, BLRX, MEIP, AYTU, CLDI, RVPH, CING, and HOTHShould you be buying Aptorum Group stock or one of its competitors? The main competitors of Aptorum Group include BiomX (PHGE), Finch Therapeutics Group (FNCH), VYNE Therapeutics (VYNE), BioLineRx (BLRX), MEI Pharma (MEIP), Aytu BioPharma (AYTU), Calidi Biotherapeutics (CLDI), Reviva Pharmaceuticals (RVPH), Cingulate (CING), and Hoth Therapeutics (HOTH). These companies are all part of the "pharmaceutical products" industry. Aptorum Group vs. Its Competitors BiomX Finch Therapeutics Group VYNE Therapeutics BioLineRx MEI Pharma Aytu BioPharma Calidi Biotherapeutics Reviva Pharmaceuticals Cingulate Hoth Therapeutics Aptorum Group (NASDAQ:APM) and BiomX (NYSEMKT:PHGE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment. Which has stronger earnings and valuation, APM or PHGE? Aptorum Group has higher revenue and earnings than BiomX. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptorum Group$430K42.22-$4.27MN/AN/ABiomXN/AN/A-$28.32M-$0.85-0.48 Do insiders and institutionals believe in APM or PHGE? 3.8% of Aptorum Group shares are owned by institutional investors. Comparatively, 40.6% of BiomX shares are owned by institutional investors. 64.0% of Aptorum Group shares are owned by insiders. Comparatively, 1.2% of BiomX shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts recommend APM or PHGE? BiomX has a consensus target price of $21.00, indicating a potential upside of 5,085.19%. Given BiomX's stronger consensus rating and higher probable upside, analysts clearly believe BiomX is more favorable than Aptorum Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BiomX 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to APM or PHGE? In the previous week, Aptorum Group had 3 more articles in the media than BiomX. MarketBeat recorded 7 mentions for Aptorum Group and 4 mentions for BiomX. Aptorum Group's average media sentiment score of 1.89 beat BiomX's score of 0.15 indicating that Aptorum Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptorum Group 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BiomX 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is APM or PHGE more profitable? Aptorum Group's return on equity of 0.00% beat BiomX's return on equity.Company Net Margins Return on Equity Return on Assets Aptorum GroupN/A N/A N/A BiomX N/A -127.82%-56.50% Which has more risk & volatility, APM or PHGE? Aptorum Group has a beta of -0.17, meaning that its stock price is 117% less volatile than the S&P 500. Comparatively, BiomX has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. SummaryAptorum Group beats BiomX on 7 of the 12 factors compared between the two stocks. Get Aptorum Group News Delivered to You Automatically Sign up to receive the latest news and ratings for APM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APM vs. The Competition Export to ExcelMetricAptorum GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.70M$2.44B$5.56B$9.30BDividend YieldN/A1.79%4.23%4.03%P/E RatioN/A9.1728.6319.67Price / Sales42.22745.64439.23185.66Price / CashN/A164.3436.0257.93Price / Book1.544.698.185.64Net Income-$4.27M$30.99M$3.23B$257.73M7 Day Performance277.00%1.06%-0.20%0.21%1 Month Performance200.27%8.23%5.43%8.47%1 Year Performance-21.28%-5.71%26.39%13.93% Aptorum Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APMAptorum Group1.5597 of 5 stars$3.39+249.9%N/A-77.5%$17.70M$430K0.0030News CoveragePositive NewsGap UpTrading HaltedHigh Trading VolumePHGEBiomX2.2218 of 5 stars$0.39-46.7%$21.00+5,229.9%-88.6%$10.86MN/A-0.56120FNCHFinch Therapeutics Group0.7713 of 5 stars$12.75flatN/A+707.0%$20.48MN/A-1.45190VYNEVYNE Therapeutics2.9687 of 5 stars$1.33flat$6.25+369.9%-42.7%$20.23M$500K-1.3430Positive NewsGap UpBLRXBioLineRx2.6214 of 5 stars$4.71+0.1%$26.00+452.6%-85.1%$20.05M$22.34M-0.5340Gap DownMEIPMEI Pharma2.1957 of 5 stars$3.00+2.0%N/A+7.9%$19.95MN/A-0.63100Positive NewsAYTUAytu BioPharma4.2828 of 5 stars$2.17+0.7%$10.00+361.9%-23.0%$19.44M$81M-3.01160CLDICalidi Biotherapeutics0.566 of 5 stars$0.54-7.4%N/A-67.1%$19.36MN/A0.0038Gap UpRVPHReviva Pharmaceuticals3.2245 of 5 stars$0.40-6.1%$9.00+2,133.3%-68.1%$19.34MN/A-0.515Positive NewsCINGCingulate3.2878 of 5 stars$4.48-5.4%$26.00+481.0%+1,032.8%$19.02MN/A-0.5320HOTHHoth Therapeutics3.273 of 5 stars$1.42-1.0%$4.00+182.7%+52.3%$18.56MN/A-1.234Positive News Related Companies and Tools Related Companies PHGE Competitors FNCH Competitors VYNE Competitors BLRX Competitors MEIP Competitors AYTU Competitors CLDI Competitors RVPH Competitors CING Competitors HOTH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APM) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptorum Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptorum Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
